UBS Securities Co., Ltd.
Verification Opinion on the Termination of Some Fund Investment Projects of Enbio Technology Co., Ltd. and Continued Deposit of Remaining Fund into Special Account
UBS Securities Co., Ltd. ("UBS Securities," "Sponsor") as the sponsor of Enbio Technology Co., Ltd. ("Enbio Technology," "Company") for its initial public offering of stocks on the ChiNext Market, in accordance with the "Administrative Measures for Securities Issuance and Listing Sponsorship," "Supervision Regulations for Listed Company Fund Raising," "ChiNext Market Stock Listing Rules of the Shenzhen Stock Exchange," and "ChiNext Market Listed Company Self-Regulatory Guidelines No. 2 - Standardized Operation of ChiNext Market Listed Companies," and other relevant laws, regulations, and normative documents, has verified the matter of Enbio Technology terminating some fund investment projects and continuing to deposit the remaining fund into a special account for fund management, and hereby issues this verification opinion. The specific verification situation is as follows:
I. Basic Situation of Raised Funds
As approved by the China Securities Regulatory Commission's "Approval on the Registration of Enbio Technology Co., Ltd.'s Initial Public Offering of Stocks" (Document No. [2022]926), the Company issued 37,123,013 ordinary shares (A shares) at an issuance price of RMB 43.32 per share, with a total raised fund of RMB 1,608.1689 million. After deducting issuance expenses (excluding VAT) of RMB 150.8705 million, the net raised fund amounted to RMB 1,457.2984 million, with an over-raised fund of RMB 147.6392 million. The raised funds were transferred to the Company's designated account on August 12, 2022. Tianzhi International Certified Public Accountants (Special General Partnership) audited the receipt of the raised funds for this issuance and issued the "Capital Verification Report" (No. [2022]38658) on August 12, 2022.
The Company and its subsidiaries implementing the fund-raising investment projects have opened special accounts for raised funds, which are stored in a dedicated account. Tripartite/quadpartite custody agreements have been signed with the sponsor and the commercial banks where the raised funds are deposited.
II. Specific Situation of Fund-Raising Investment Projects
According to the "Prospectus of Enbio Technology Co., Ltd. for Initial Public Offering of Stocks on the ChiNext Market," the raised funds from the Company's current issuance, after deducting issuance expenses, will be used for the construction of the following fund-raising investment projects:
| Serial No. | Project Name | Total Investment Amount (RMB Million) | Amount of Raised Funds Invested (RMB Million) |
|---|---|---|---|
| 1 | Tangxia Production Base Construction Project | 24,841.18 | 24,841.18 |
| 2 | Integrated Biometric IoT Intelligent Industry Base Construction Project | 43,689.94 | 43,689.94 |
| 3 | US Manufacturing Plant Construction Project | 17,392.21 | 17,392.21 |
| 4 | R&D Center Construction Project | 18,240.58 | 18,240.58 |
| 5 | Global Marketing Service Network Construction Project | 26,802.01 | 26,802.01 |
| 6 | Over-raised Funds | 14,763.92 | 14,763.92 |
| Total | 145,729.84 | 145,729.84 |
As of March 31, 2026, the fund-raising investment projects and fund usage plan for the Company's initial public offering of stocks are as follows: